FDA clears Veppanu, the first protein degrader to reach market — but no commercial partner in sight. Q1 biopharma M&A hits $84B as patent cliff urgency drives a mega year. Plus: Truqap wins 7-1 ODAC vote in prostate cancer, Auvelity expands into Alzheimer's agitation, and Summit's ivonescimab stumbles before ASCO.
Auto-generated from the episode script. Deal names link to their scorecard in the database.
The FDA just approved the first protein degrader ever to reach the market — and the two companies behind it still can't find anyone to sell it.
Plus Summit stumbles on ivonescimab, ArchiMed takes Esperion private for 1.1 billion, and Reuters says pharma M&A is tracking toward a quarter-trillion-dollar year. Let's close out the week.
Welcome to The Pharma Closeout for Friday, May 1st, 2026. I'm Alex Mercer.
And I'm Maya Patel. Let's get into it.
The FDA today cleared Veppanu — vepdegestrant, developed by Arvinas and Pfizer — as a second-line treatment for ER-positive, HER2-negative breast cancer with ESR1 mutations. It's another novel drug approval this year, but this one carries weight well beyond the indication. Veppanu is the first PROTAC ever cleared by a regulatory agency anywhere. A new drug modality just arrived on the market.
The modality milestone is genuine — no one should undersell it. But the commercial picture undercuts the celebration. Endpoints flagged this approval came despite what they called underwhelming data. The pivotal trial demonstrated improved progression-free survival over fulvestrant across a substantial patient population — yet neither Pfizer nor Arvinas has a commercial partner lined up. Both companies have publicly acknowledged they're still searching for one.
Think about how unusual that is. The FDA just validated targeted protein degradation as a viable therapeutic approach — the proof point the entire modality has been waiting for — and the two companies that built it are handing off commercialization to a partner they haven't found yet.
The comparator arm warrants scrutiny too. Fulvestrant monotherapy in ESR1-mutated disease is a low bar in 2026. Prescribers in this space are already sequencing through CDK4/6 combinations and oral SERDs. Demonstrating a PFS benefit over fulvestrant alone won't automatically translate into formulary positioning when the competitive set has moved well past that benchmark.
So the dual read: for the PROTAC modality broadly, this is unambiguous regulatory validation. Every degrader program in development just got its proof point, and the pathway through regulatory agencies is now established.
For Veppanu the product, the calculus is different. A drug searching for a commercial partner is a drug without a launch timeline. And in ER-positive breast cancer, competitive positioning windows close fast.
Shifting to the deal landscape — that same commercial urgency is playing out at scale this week. Reuters published an analysis today calling 2026 a mega year for pharma M&A. First-quarter biotech deal value surged significantly—nearly double the prior year and the strongest opening quarter in several years. If the pace holds, the full-year total could exceed 250 billion. Lilly, Gilead, and Merck are leading the charge. Let's bring in Marcus Webb on what's structurally different this cycle.
A substantial revenue base faces loss of exclusivity in the coming years. Keytruda, the GLP-1 franchises, major oncology and immunology brands — the exposure is broad. But what separates 2026 from prior patent cliff cycles is the breadth of the response. Buyers aren't confining themselves to oncology. They're pushing into neurology, cardiovascular, and rare disease at real scale — and biotech valuations, while they've recovered from the 2022 trough, remain cooperative enough that acquirers can pay meaningful premiums and still make the return math work.
The deal tape this week makes the case. Chiesi signed a 1.9-billion-dollar deal for KalVista and its oral hereditary angioedema drug — the fifth biotech acquisition that week alone, per BioPharma Dive. Teva paid a substantial upfront fee for Emalex Biosciences and its NDA-ready Tourette drug ecopipam, with additional commercial milestones and royalty-based payments. And today, ArchiMed takes Esperion private in a deal valued at up to approximately 1.1 billion — Esperion shares experienced a significant jump on the announcement.
The Esperion deal is the one I keep circling. A healthcare PE firm paying up to 1.1 billion to take a specialty cholesterol franchise private — that's ArchiMed running a fundamentally different capital allocation model than the public market was willing to support. They see commercial runway in the bempedoic acid platform that Wall Street apparently wasn't patient enough to fund.
Also this week: Ligand Pharmaceuticals acquiring fellow royalty aggregator XOMA for 739 million at 39 dollars a share — consolidating the royalty model itself. Pfizer's Elrexfio hit its primary endpoint in a Phase 3 blood cancer trial after at least one prior therapy line. Avalyn Pharma banked 300 million in an IPO for inhaled pulmonary fibrosis drugs — part of a year where six biotechs have already crossed 300 million at IPO. And Lilly capped the week with another blowout quarter — Mounjaro driving strong international growth, full-year guidance raised on both profit and revenue, with all eyes turning to the Foundayo launch.
The through-line across all of it: acquirers and investors are paying premiums for near-term commercial assets, not early-stage science. That's the patent cliff manifesting as deal discipline, not panic.
On the regulatory front — Maya, the FDA had a full slate today.
A packed one. AstraZeneca's Truqap cleared ODAC with strong committee support — recognizing a favorable benefit-risk for capivasertib plus abiraterone and ADT in PTEN-deficient metastatic hormone-sensitive prostate cancer.
Seven to one is as clean as advisory committee signals get. How does this reshape AZ's position?
It gives them a biomarker-gated prostate franchise that sidesteps the crowded androgen receptor space entirely. PTEN loss is enriched in de novo metastatic presentations, and selecting for that alteration up front means a cleaner efficacy signal than biomarker-unselected approaches deliver. If the FDA follows the panel at that margin — and they typically do when the vote is this lopsided — AZ locks in a differentiated mHSPC position with a companion diagnostic moat around it.
Two more. Axsome's Auvelity — dextromethorphan-bupropion — picked up an FDA label expansion into Alzheimer's-associated agitation, adding a second indication beyond MDD. And on the opposite end of the spectrum, Amgen filed a supplemental label update for Tavneos while the FDA escalates its push to withdraw the drug over alleged data manipulation.
Auvelity in Alzheimer's agitation fills a gap that prescribers and caregivers feel acutely — there are virtually no approved pharmacological options for that population. Axsome just opened a meaningful second commercial lane with genuine unmet need behind it. On Tavneos, the standoff is procedurally extraordinary. The FDA alleging data integrity issues while the sponsor refuses to withdraw — however that resolves, it sets enforcement precedent for post-approval oversight that extends well beyond one molecule.
And one more — UniQure announced plans to seek UK approval for its Huntington's disease gene therapy. Per BioPharma Dive, this would be the first regulatory submission anywhere for that treatment, though it faces an uncertain path in the U.S.
A symbolic filing, but strategically deliberate. Establishing a regulatory foothold outside the U.S. changes the negotiating dynamics with the FDA — and for the Huntington's community, any forward motion shifts the conversation.
Looking ahead — Summit Therapeutics is the name to track into next week. Shares tumbled today on an apparent interim miss for ivonescimab — BioPharma Dive called it a self-inflicted stumble. But Summit still holds a plenary ASCO slot, the most visible stage in clinical oncology, so the data narrative is far from finished. Separately, Moderna is in active FDA discussions over post-marketing COVID vaccine data with eyes on wider access, while the company affirms 10 percent revenue growth for 2026 driven by international vaccine sales offsetting U.S. declines.
Summit's year hinges on whether the ASCO data set reframes today's narrative or confirms it. The PD-1/VEGF bispecific space is getting more crowded by the month — BeOne recently entered with a trispecific — so Summit's window for a recovery story keeps narrowing.
On the obesity front, Amgen launched a late-stage trial enrolling patients switching from rival drugs — not a general population study, a deliberate positioning play. And Samsung Biologics workers started a five-day strike over wages. Samsung is one of the largest CDMO operations in global biologics.
The Amgen switch study tells you exactly where the next obesity battleground forms — demonstrating tolerability and efficacy in patients already established on rival therapy is the hardest clinical bar, but it's the most commercially relevant proof point. And if Samsung's strike extends past this weekend, the manufacturing disruption could cascade through production timelines for companies that don't even know they're exposed.
That is your Pharma Closeout for Friday, May 1st. The first PROTAC made it to market with Veppanu, the M&A engine is running at 84 billion a quarter, Truqap sailed through ODAC 7 to 1, and Axsome quietly opened a second franchise with Auvelity. If this briefing keeps you sharp heading into the weekend, follow us on Spotify and drop a rating — it makes a real difference. Full weekend wrap coming Sunday.
Go enjoy your weekend. We'll see you Sunday.
The daily Closeout in under 15 minutes — trial readouts, FDA decisions, and the deal math behind them. Free.
Subscribe →